EX-10.2 8 ff12018a1ex10-2_tiziana.htm LICENSE AND SUBLICENSE AGREEMENT RELATING TO CD3 (NI-0401) BETWEEN NOVIMMUNE SA AND TIZIANA LIFE SCIENCES PLC, DATED DECEMBER 2014 LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • May 5th, 2020 • England and Wales
This License and Sublicense Agreement (“Agreement”) is made effective as of December 19th, 2014 (“Effective Date”) by and between on the one hand NovImmune S.A., 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland (“Licensor”), and Tiziana Life Sciences Plc, 18 South Street, Mayfair, London, W1K 1DG, UK (“Licensee”). Licensor and Licensee are each hereafter referred to individually as a “Party” arid together as the “Parties.”
RECITALSLicense and Sublicense Agreement • May 11th, 2001 • Quantech LTD /Mn/ • Surgical & medical instruments & apparatus • New York
LICENSE AND SUBLICENSE AGREEMENT BETWEEN LYOTROPIC THERAPEUTICS, INC. AND EAGLE PHARMACEUTICALS, INC.License and Sublicense Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This LICENSE AND SUBLICENSE AGREEMENT (this “Agreement”) is made and entered into this 16th day of October, 2008 (the “Effective Date”), between Lyotropic Therapeutics, Inc., a Virginia corporation (“Lyotropic”), and Eagle Pharmaceuticals, Inc., a Delaware corporation (“Eagle”).
EX-10.23 4 dex1023.htm AMENDED AND RESTATED LICENSE AND SUBLICENSE AGREEMENT Execution Copy CONFIDENTIAL TREATMENT REQUESTED – CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION AMENDED AND...License and Sublicense Agreement • May 5th, 2020 • Utah
THIS LICENSE AND SUBLICENSE AGREEMENT (“Agreement”) is entered into as of this 2nd day of November, 2006 (“Execution Date”), by and between Raser – Power Systems, LLC (a subsidiary of Raser Technologies, Inc.), a Delaware limited liability company with its principal offices located at 5152 North Edgewood Drive, Suite 375, Provo, Utah 84604 (“Sub-licensee”) and Recurrent Engineering, L.L.C., (f/k/a Recurrent Resources LLC), a Delaware limited liability company, having its principal offices located at 11814 Election Road, Suite 100, Draper, Utah 84020 (“Sub-licensor”). Sub-licensor and Sub-licensee are sometimes hereinafter collectively referred to as the “Parties,” and individually as a “Party.”
EX-10.1 2 dex101.htm LICENSE AND SUBLICENSE AGREEMENT [CONFORMED COPY REFLECTING ALL AMENDMENTS THROUGH NOVEMBER 17, 2004] LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • May 5th, 2020 • New York
This Agreement is entered into as of April 12, 2000 between Licensor AMBI Inc., a New York corporation (“AMBI”), and Licensee ImmuCell Corporation, a Delaware corporation (“IC”) (collectively “parties”).
FIRST AMENDMENT TO THE LICENSE AND SUBLICENSE AGREEMENT BY AND BETWEEN ON TARGET THERAPEUTICS LLC AND OKYO PHARMA LIMITEDLicense and Sublicense Agreement • March 4th, 2022 • OKYO Pharma LTD • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO THE LICENSE AND SUBLICENSE AGREEMENT (“First Amendment”) is dated as of March 25, 2021 (the “First Amendment Effective Date”) by and between On Target Therapeutics, LLC, 15 Wynnewood Road, Wellesley, MA 02481 and (“On Target”) and OKYO Pharma Limited, Martello Court, Admiral Park, St. Peter Port, Guernsey, GY1 3HB (“OKYO”).
EX-10.1 2 dex101.htm LICENSE AND SUBLICENSE AGREEMENT, DATED OCTOBER 28, 2003 LICENSE AND SUBLICENSE AGREEMENT by and between CPEC L.L.C. and ARCA DISCOVERY, INC.License and Sublicense Agreement • May 5th, 2020 • New York
LICENSE AGREEMENT (this “Agreement”) effective as of October 28, 2003 (“Effective Date”), by and between CPEC, L.L.C., a Delaware limited liability company (“CPEC”) having an office at 99 Hayden Avenue, Suite 200, Lexington, MA 02421 (“CPEC”) and ARCA Discovery, Inc., a corporation organized and existing under the laws of the State of Colorado and having its principal office at 12635 East Montview Boulevard, Suite 100, Aurora, CO 80010 (“ARCA”).
AMENDMENT TO THE LICENSE AND SUBLICENSE AGREEMENT BY AND BETWEEN CPEC LLC AND ARCA DISCOVERY INC.License and Sublicense Agreement • May 15th, 2009 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
THIS AMENDMENT (the “Amendment”), dated as of February, 22, 2006 (“Amendment Effective Date”), by and between CPEC LLC, a Delaware limited liability company having an office at 33 Hayden Avenue, Lexington, MA 02421 (“CPEC”) and ARCA Discovery, Inc., a corporation organized and existing under the laws of the State of Colorado and having its principal office at 1400 Sixteenth Street, Suite 220, Denver, Colorado 80202 (“ARCA”), amends the License and Sublicense Agreement effective as of October 28, 2003 (the “License Agreement”) by and between CPEC and ARCA.
FERRING INTERNATIONAL CENTER SA and I-MAB LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations
THIS LICENSE AND SUBLICENSE AGREEMENT (this “Agreement”) is effective as of 4th of November 2016 (the “Effective Date”), and is by and between FERRING INTERNATIONAL CENTER SA, a company organised and existing under the laws of Switzerland and having its principal place of business at Chemin de la Vergognausaz 50 CH-1162 Saint-Prex Switzerland (“Ferring”) and I-MAB, a company organised and existing under the laws of Cayman Islands and having its principal place of business at Floor 4, Willow House, Cricket Square, P 0 Box 2804, Grand Cayman KY1-1112, Cayman Islands, (“I-MAB”). Each party individually may be referred to herein as a “Party” and collectively both parties may be referred to herein as the “Parties.”
FERRING INTERNATIONAL CENTER SA and I-MAB LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations
THIS LICENSE AND SUBLICENSE AGREEMENT (this “Agreement”) is effective as of 4th of November 2016 (the “Effective Date”), and is by and between FERRING INTERNATIONAL CENTER SA, a company organised and existing under the laws of Switzerland and having its principal place of business at *** (“Ferring”) and I-MAB, a company organised and existing under the laws of Cayman Islands and having its principal place of business at ***, (“I-MAB”). Each party individually may be referred to herein as a “Party” and collectively both parties may be referred to herein as the “Parties.”
ContractLicense and Sublicense Agreement • May 5th, 2020 • Delaware
EX-10.1 2 ex10-1.htm MATERIAL CONTRACTS Execution Version Exhibit 10.1 EXCLUSIVE LICENSE AND SUBLICENSE AGREEMENT by and between VISTAGEN THERAPEUTICS, INC. and APOLLO BIOLOGICS LP EXCLUSIVE LICENSE AND SUBLICENSE AGREEMENT This Agreement is effective as of December 9, 2016 (the “Effective Date”), by and between VistaGen Therapeutics, Inc., a California corporation located at 343 Allerton Avenue, South San Francisco, CA 94080 (“VistaGen”), and Apollo Biologics LP, a Delaware limited partnership located at c/o Versant Venture Management, LLC, One Sansome, Suite 3630, San Francisco, CA 94104 (“Apollo”). VistaGen and Apollo are each sometimes referred to herein as a “Party” or collectively as the “Parties.” RECITALS WHEREAS, VistaGen and University Health Network (“UHN”) entered into that certain (i) License Agreement, [*****] (“License Agreement Number One”), (ii) License Agreement, [*****] (“License Agreement Number Two”), (iii) License Agreement, [*****] (“License Agreement Number Thre
LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • England
This License AND Sub-License Agreement (“Agreement”), effective as of March 19, 2018 (the “Effective Date”), is made by and between LipocureRX, Ltd., a company organized and existing under the laws of Israel (“Lipocure”), and Virpax Pharmaceuticals, Inc., a Delaware corporation (“Virpax”).
LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • May 9th, 2013 • Coronado Biosciences Inc • Pharmaceutical preparations
This License and Sublicense Agreement (“Agreement”) is entered into by and between the Parties as of the Effective Date (as defined herein).
ContractLicense and Sublicense Agreement • November 10th, 2015 • Monster Digital, Inc. • Computer storage devices
LICENSE AND SUBLICENSE AGREEMENT This License and Sublicense Agreement is made as of this 1st day of May, 2012, by and between SDJ Technologies, Inc. ("SDJ"), a corporation organized and existing under the laws of the State of Delaware, having an office at 2125 B Madera Road, Simi Valley, CA 93065, and Tandon Enterprises, Inc. ("Tandon"), a corporation organized and existing under the laws of the State of Delaware, having an office at 2125 B Madera Road, Simi Valley, CA 93065. RECITALS: WHEREAS, Tandon is the licensee of certain Patents and owner or licensor of or has the right to use or exploit, certain Technical Information (as hereinafter defined); and WHEREAS, Tandon wishes to grant to SDJ a non-exclusive sublicense to use the subject matter of certain Patents and a non-exclusive license or sublicense, as the case may be, to certain Technical Information, each to be used by SDJ in connection with the development, manufacture, sale and distribution of Products (as hereinafter define
LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • May 31st, 2016 • American Superconductor Corp /De/ • Motors & generators • New York
THIS LICENSE AND SUBLICENSE AGREEMENT (this “License”) is made effective as of March 4, 2016 (subject to the provisions of this License, the “Effective Date”) by and between AMERICAN SUPERCONDUCTOR CORPORATION, a Delaware corporation having an office and place of business at 64 Jackson Road, Devens, MA 01434 (“AMSC”), and BASF CORPORATION, a Delaware corporation having a place of business at 100 Park Avenue, Florham Park, NJ 07932 (“BASF”). AMSC and BASF are each hereinafter referred to individually as a “Party” and together as the “Parties.”
LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • February 22nd, 2024 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • California
This License and Sublicense Agreement (this “Agreement”) is entered into as of February 15, 2024 (the “Effective Date”) by Qualigen Therapeutics, Inc., a Delaware corporation (“QLGN”), on the one hand, and Pan-RAS Holdings, Inc., a New York corporation (“Pan-RAS”), on the other hand.
LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • March 16th, 2006 • Gene Logic Inc • In vitro & in vivo diagnostic substances • California
THIS LICENSE AND SUBLICENSE AGREEMENT (“AGREEMENT”) is made this 12th day of September, 2005 by and between PROMEGA CORPORATION, a corporation organized and existing under the laws of the State of Wisconsin and with principal offices located at 2800 Woods Hollow Road, Madison, Wisconsin, 53711 ("LICENSOR") and Gene Logic Inc., a corporation organized and existing under the laws of the State of Delaware with principal offices located at 610 Professional Drive, Gaithersburg, MD 20879 (“LICENSEE”) (each a “Party”, and together the “Parties” herein).
